Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LP10 + OVA8 + CpG + LLP2A
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
LP10 + OVA8 + CpG + LLP2A is a programmable peptide nucleic acid (PNA)-based nanovaccine (PVN) designed for targeted cancer immunotherapy. The platform utilizes an 11-mer PNA scaffold (LP10) to facilitate the precise assembly of three functional components: a PNA-modified ovalbumin antigenic peptide (OVA8, containing the SIINFEKL sequence), a CpG oligodeoxynucleotide adjuvant, and a PNA-derivatized LLP2A ligand. The LLP2A component specifically targets the activated α4β1 integrin (also known as VLA-4) expressed on the surface of immune cells and certain tumor cells, such as melanoma. This targeted approach enhances the delivery of antigens and adjuvants to dendritic cells, thereby boosting antigen presentation and eliciting potent CD8+ T cell and natural killer (NK) cell immune responses. Preclinical studies in B16-OVA syngeneic melanoma models have demonstrated that this nanovaccine can induce significant tumor regression and prolong survival.
- Other names
- PNA-based vaccine nanoplatformLP10-OVA8-CpG-LLP2ALP-10-OVA8-CpG-LLP2ALP 10-OVA8-CpG-LLP2A
02
Targets
α4β1 (Integrin α4β1)TLR9 (Toll-like receptor 9)MHC I (MHC class I})
Beyond the preview
Go deeper on LP10 + OVA8 + CpG + LLP2A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LP10 + OVA8 + CpG + LLP2A.